These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 23992876)

  • 1. Pharmacokinetic analysis of enoxaparin in a term neonate and review of literature.
    Mateos MK; Wright FA; Cohn RJ
    Thromb Res; 2013 Oct; 132(4):487-9. PubMed ID: 23992876
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation of a pharmacokinetic program for adjusting enoxaparin in renal impairment.
    Nagge J; Fernandes O; Huh J
    Am Heart J; 2005 Mar; 149(3):e21; author reply e23-4. PubMed ID: 15864222
    [No Abstract]   [Full Text] [Related]  

  • 3. Novel uses of insulin syringes to reduce dosing errors: a retrospective chart review of enoxaparin whole milligram dosing.
    Bauman ME; Black KL; Bauman ML; Belletrutti M; Bajzar L; Massicotte MP
    Thromb Res; 2009 Apr; 123(6):845-7. PubMed ID: 19038418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of the biological activity of 2 formulations of enoxaparin in 12 healthy volunteers.
    Sharma V; Madhu S; Natarajan P; Muniyandi G; Jaiswal V; Saxena R
    Clin Appl Thromb Hemost; 2010 Aug; 16(4):387-93. PubMed ID: 19671565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective evaluation of a pharmacokinetic program for adjusting enoxaparin in renal impairment.
    Kruse MW; Lee JJ
    Am Heart J; 2004 Oct; 148(4):582-9. PubMed ID: 15459586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reliable anticoagulation with enoxaparin in patients undergoing percutaneous coronary intervention: The pharmacokinetics of enoxaparin in PCI (PEPCI) study.
    Martin JL; Fry ET; Sanderink GJ; Atherley TH; Guimart CM; Chevalier PJ; Ozoux ML; Pensyl CE; Bigonzi F
    Catheter Cardiovasc Interv; 2004 Feb; 61(2):163-70. PubMed ID: 14755805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enoxaparin should be used cautiously in patients with end-stage renal disease.
    Kalus JS; Spencer AP
    Pharmacotherapy; 2001 Aug; 21(8):1015-6; author reply 1017-9. PubMed ID: 11718491
    [No Abstract]   [Full Text] [Related]  

  • 8. Bioequivalence of generic and branded subcutaneous enoxaparin: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy Chinese male subjects.
    Feng L; Shen-Tu J; Liu J; Chen J; Wu L; Huang M
    Clin Ther; 2009 Jul; 31(7):1559-67. PubMed ID: 19695405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experience with intravenous enoxaparin in critically ill infants and children.
    Crary SE; Van Orden H; Journeycake JM
    Pediatr Crit Care Med; 2008 Nov; 9(6):647-9. PubMed ID: 18838932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Routine laboratory monitoring for low-molecular-weight heparin prophylaxis in burns? Not so fast!
    Lundy JB; Lairet K; Chung KK; Renz EM
    J Burn Care Res; 2011; 32(4):e155. PubMed ID: 21577136
    [No Abstract]   [Full Text] [Related]  

  • 11. A bioavailability study in the proposed patient population--with much more needed now.
    Freedman MD
    Crit Care Med; 2003 May; 31(5):1588-9. PubMed ID: 12771643
    [No Abstract]   [Full Text] [Related]  

  • 12. Administration of enoxaparin by continuous infusion in a naturalistic setting: analysis of renal function and safety.
    Kane-Gill SL; Feng Y; Bobek MB; Bies RR; Pruchnicki MC; Dasta JF
    J Clin Pharm Ther; 2005 Jun; 30(3):207-13. PubMed ID: 15896237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo evaluation of enoxaparin removal by continuous renal replacement therapies with acrylonitrile and polysulfone membranes.
    Isla A; Gascón AR; Maynar J; Arzuaga A; Corral E; Martín A; Solinís MA; Muñoz JL
    Clin Ther; 2005 Sep; 27(9):1444-51. PubMed ID: 16291417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticoagulation in cirrhosis patients: what don't we know?
    Northup PG; Intagliata NM
    Liver Int; 2011 Jan; 31(1):4-6. PubMed ID: 21092072
    [No Abstract]   [Full Text] [Related]  

  • 15. Dosing strategy for enoxaparin in patients with renal impairment presenting with acute coronary syndromes.
    Green B; Greenwood M; Saltissi D; Westhuyzen J; Kluver L; Rowell J; Atherton J
    Br J Clin Pharmacol; 2005 Mar; 59(3):281-90. PubMed ID: 15752373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of thromboelastography to demonstrate persistent anticoagulation after stopping enoxaparin.
    Simons R; Mallett SV
    Anaesthesia; 2007 Nov; 62(11):1175-8. PubMed ID: 17924901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topical delivery of enoxaparin using nanostructured lipid carrier.
    Jain A; Mehra NK; Nahar M; Jain NK
    J Microencapsul; 2013; 30(7):709-15. PubMed ID: 23534492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alginate coated chitosan core shell nanoparticles for oral delivery of enoxaparin: in vitro and in vivo assessment.
    Bagre AP; Jain K; Jain NK
    Int J Pharm; 2013 Nov; 456(1):31-40. PubMed ID: 23994363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fisher information matrix for non-linear mixed-effects models: evaluation and application for optimal design of enoxaparin population pharmacokinetics.
    Retout S; Mentré F; Bruno R
    Stat Med; 2002 Sep; 21(18):2623-39. PubMed ID: 12228881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarkers and coagulation tests for assessing the biosimilarity of a generic low-molecular-weight heparin: results of a study in healthy subjects with enoxaparin.
    Kuczka K; Harder S; Picard-Willems B; Warnke A; Donath F; Bianchini P; Parma B; Blume H
    J Clin Pharmacol; 2008 Oct; 48(10):1189-96. PubMed ID: 18716314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.